Primary Ovarian Insufficiency: Why Her Hormone Therapy Isn't Menopausal HRT
A 28-year-old with primary ovarian insufficiency is offered the same menopausal HRT regimen her mother takes — a dosing target built for a 51-year-old's remaining biology, not hers.
Renata S., a 28-year-old woman, works as a landscape architect and had spent the better part of the past year attributing her missed periods to the physical demands of a job that has her on-site through most of the growing season — until the hot flashes started, which nothing about fieldwork explained. Her cycles stopped entirely eight months ago. Her mother went through menopause at 52 and, when Renata mentioned the hot flashes, handed her an old prescription bottle and said this was probably the same thing, just early.
It isn't quite the same thing, and the difference is what actually drives today's decision. Two FSH levels six weeks apart both came back above 40 IU/L with estradiol under 20 pg/mL — confirmed primary ovarian insufficiency, not early menopause in the sense her mother meant it. The distinction matters pharmacologically: a woman diagnosed with POI at 28 has, under ordinary biology, roughly two more decades of endogenous estrogen exposure ahead of her than her ovaries are now going to provide, and the bone-density and cardiovascular-risk literature specific to POI — not the general menopausal-HRT literature her mother's regimen was drawn from — is what actually describes what happens to a woman in that gap if she's under- replaced. Her baseline DEXA already shows a lumbar spine Z-score of -1.6 — the age-matched comparison that applies before menopause, rather than the T-score used after it — still within the expected range for her age, but at its low end and consistent with roughly eight months of unreplaced estrogen deficiency.
The workup that followed the confirmed diagnosis found no clear cause — a normal karyotype, a negative FMR1 premutation screen, and no personal or family history suggesting an autoimmune process, which leaves her, like the majority of POI cases, without a specific named etiology to point to. Whether that unresolved "why" should change what happens next has an honest answer, and it mostly doesn't: the treatment question in front of the team today turns on her age and her ovaries' current output, not on the still-unidentified reason they stopped working early. What the negative workup cannot supply is a stopping rule: with no identified etiology there is no marker to follow that would say when her replacement has been adequate, leaving her Z-score and her symptoms as the only two readouts available for the next two decades.
Clinic visit, mother's prescription in hand
My instinct is the lowest effective dose that controls her symptoms — the same instinct every menopausal HRT conversation trains into a generalist, because it's correct for that population. I'd want to hear directly why that instinct is wrong here before overriding it, rather than just defaulting to more because she's younger.
If Renata were 51, I wouldn't be raising this at all — lowest effective dose is genuinely the right target for someone at the natural age of menopause.
It's wrong here because the target isn't symptom control, it's replacement — restoring roughly what her ovaries would still be producing on their own for the next twenty-plus years. The POI-specific literature (distinct from the WHI-era menopausal HRT data her mother's regimen was drawn from) supports physiologic-dose transdermal estradiol, continued to the average age of natural menopause around 51, not a several-year symptom-control course. Her lumbar Z-score is already -1.6 at 28 — that's what eight unreplaced months looks like, and it's the outcome menopausal-dose thinking would leave running for decades, not years.
I'd push back specifically on "lowest effective dose" as the right frame at all here — effective for what she's actually being treated for is a materially higher bar than effective for hot flashes.
One more substitution worth naming before we write anything: her mother's bottle, or a combined OCP if someone reaches for that instead, isn't a lighter version of the same answer. A combined OCP's estrogen dose and cyclic delivery were built for contraception in a woman whose ovaries are still working — not for replacing an ovary that's already stopped. Physiologic transdermal estradiol with cyclic progestin is a different pharmacologic target entirely, and conflating the two because both come as a daily pill is exactly the mistake her mother's well-meaning hand-off risks.
Agreed within the visit: physiologic-dose transdermal estradiol with cyclic micronized progesterone, planned to continue to approximately age 51 rather than a menopausal-length symptom-control course, with a repeat DEXA at one year to confirm the bone-density trajectory has actually reversed rather than assuming the dose choice alone guarantees it.
All three voices converged on the same regimen once the age-appropriate target was named directly — the disagreement in this case was never really about which drug, but about which literature (menopausal HRT vs. POI-specific) should set the dose and duration, and that question resolved once stated plainly rather than left implicit in a reflexive "lowest effective dose" default.